Bildkälla: Stockfoto

Spago Nanomedical Q4: Progressing with Tumorad and Pegfosimer Manganese (SpagoPix) - Redeye

Spago Nanomedical's lead candidate Tumorad are progressing towards initial results by mid-2024 and Pegfosimer Manganese (SpagoPix) has progressed to a stage where Spago Nanomedical can engage with potential partners. The OPEX base is contained at SEK 12m in Q4.

Spago Nanomedical's lead candidate Tumorad are progressing towards initial results by mid-2024 and Pegfosimer Manganese (SpagoPix) has progressed to a stage where Spago Nanomedical can engage with potential partners. The OPEX base is contained at SEK 12m in Q4.
Börsvärldens nyhetsbrev
ANNONSER